370 related articles for article (PubMed ID: 32257106)
1.
Xu M
Cell Biosci; 2020; 10():48. PubMed ID: 32257106
[TBL] [Abstract][Full Text] [Related]
2. Inducing CCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology.
Qi C; Li D; Jiang X; Jia X; Lu L; Wang Y; Sun J; Shao Y; Wei M
Mol Ther Nucleic Acids; 2018 Sep; 12():267-274. PubMed ID: 30195765
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
5. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
6. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
7. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
8. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
9. Islamic Perspectives on CRISPR/Cas9-Mediated Human Germline Gene Editing: A Preliminary Discussion.
Isa NM; Zulkifli NA; Man S
Sci Eng Ethics; 2020 Feb; 26(1):309-323. PubMed ID: 30830592
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
11. Genome editing of CCR5 by AsCpf1 renders CD4
Liu Z; Liang J; Chen S; Wang K; Liu X; Liu B; Xia Y; Guo M; Zhang X; Sun G; Tian G
Cell Biosci; 2020; 10():85. PubMed ID: 32670545
[TBL] [Abstract][Full Text] [Related]
12. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.
Nerys-Junior A; Braga-Dias LP; Pezzuto P; Cotta-de-Almeida V; Tanuri A
Genet Mol Biol; 2018; 41(1):167-179. PubMed ID: 29583154
[TBL] [Abstract][Full Text] [Related]
14. Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos.
Schmidt JK; Strelchenko N; Park MA; Kim YH; Mean KD; Schotzko ML; Kang HJ; Golos TG; Slukvin II
Sci Rep; 2020 Oct; 10(1):18457. PubMed ID: 33116147
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.
Donyavi T; Bokharaei-Salim F; Nahand JS; Garshasbi S; Esghaei M; Sadeghi M; Jamshidi S; Khanaliha K
J Med Virol; 2020 Aug; 92(8):1158-1164. PubMed ID: 31854469
[TBL] [Abstract][Full Text] [Related]
16. Bioethical issues in genome editing by CRISPR-Cas9 technology.
Ayanoğlu FB; Elçin AE; Elçin YM
Turk J Biol; 2020; 44(2):110-120. PubMed ID: 32256147
[TBL] [Abstract][Full Text] [Related]
17. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus.
Kang H; Minder P; Park MA; Mesquitta WT; Torbett BE; Slukvin II
Mol Ther Nucleic Acids; 2015 Dec; 4():e268. PubMed ID: 26670276
[TBL] [Abstract][Full Text] [Related]
18. The Wisdom of Germline Editing: An Ethical Analysis of the Use of CRISPR-Cas9 to Edit Human Embryos.
Gumer JM
New Bioeth; 2019 Jun; 25(2):137-152. PubMed ID: 31130112
[TBL] [Abstract][Full Text] [Related]
19. Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV-1 infection.
Deng Q; Chen Z; Shi L; Lin H
Rev Med Virol; 2018 Sep; 28(5):e1998. PubMed ID: 30024073
[TBL] [Abstract][Full Text] [Related]
20. Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3'A genetic polymorphisms in HIV-1 infected and uninfected patients in the west region of Cameroon.
Nkenfou CN; Mekue LC; Nana CT; Kuiate JR
BMC Res Notes; 2013 Jul; 6():288. PubMed ID: 23880174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
